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Abstract
Dysferlinopathies is a group of autosomal-recessive inherited neuromuscular diseases, which
are  characterized  by  defect  in  mRNA expression  or  in  functionioning  of  dysferlin  protein,
appearing in about 1/200 000 births. Dysferlin is encoded by DYSF gene (Dystrophy-associated
fer-1- like). It's disruption can cause various types of primary dysferlinopathies, which include
Miyoshi  myopathy  (MM),  Limb-girdle  Muscular  Dystrophy  type  2B  (LGMD2B)  and  distal
myopathy with anterior tibial onset. Also, dysferlin deficiency can be associated with other
diseases, such as caveolin- And calpainopathies. Here we discuss dysferlin protein structure and
function, it's clinical phenotypes, known animal models and developing treatment strategies for
dysferlinopathies. © Human stem cells institute, 2013.
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